Albert David Ltd
Incorporated in 1938, Albert David
Ltd is in the business of manufacturing pharmaceutical products[1]
- Market Cap ₹ 723 Cr.
- Current Price ₹ 1,267
- High / Low ₹ 1,754 / 911
- Stock P/E 10.6
- Book Value ₹ 724
- Dividend Yield 0.90 %
- ROCE 27.8 %
- ROE 21.7 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company has delivered good profit growth of 22.9% CAGR over last 5 years
Cons
- The company has delivered a poor sales growth of 2.73% over past five years.
- Earnings include an other income of Rs.71.0 Cr.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
261 | 287 | 317 | 318 | 293 | 285 | 316 | 320 | 246 | 313 | 341 | 362 | 365 | |
236 | 254 | 281 | 286 | 266 | 267 | 286 | 289 | 227 | 272 | 297 | 315 | 340 | |
Operating Profit | 26 | 33 | 37 | 31 | 27 | 18 | 30 | 30 | 19 | 41 | 44 | 47 | 25 |
OPM % | 10% | 11% | 12% | 10% | 9% | 6% | 10% | 10% | 8% | 13% | 13% | 13% | 7% |
2 | 1 | 2 | 43 | 8 | 9 | 15 | 7 | 17 | 16 | 15 | 58 | 71 | |
Interest | 4 | 4 | 3 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 |
Depreciation | 11 | 11 | 15 | 9 | 8 | 8 | 7 | 8 | 8 | 9 | 9 | 7 | 7 |
Profit before tax | 13 | 18 | 20 | 63 | 26 | 18 | 38 | 29 | 27 | 47 | 51 | 97 | 89 |
Tax % | 36% | 32% | 32% | 24% | 39% | 45% | 29% | 34% | 19% | 25% | 29% | 22% | |
9 | 13 | 14 | 48 | 16 | 10 | 27 | 19 | 22 | 35 | 36 | 75 | 69 | |
EPS in Rs | 15.00 | 22.02 | 24.00 | 84.10 | 27.96 | 17.24 | 46.68 | 33.59 | 38.79 | 61.78 | 63.38 | 132.15 | 120.09 |
Dividend Payout % | 30% | 23% | 23% | 7% | 20% | 32% | 13% | 21% | 15% | 15% | 14% | 9% |
Compounded Sales Growth | |
---|---|
10 Years: | 2% |
5 Years: | 3% |
3 Years: | 14% |
TTM: | 7% |
Compounded Profit Growth | |
---|---|
10 Years: | 20% |
5 Years: | 23% |
3 Years: | 52% |
TTM: | 18% |
Stock Price CAGR | |
---|---|
10 Years: | 18% |
5 Years: | 26% |
3 Years: | 30% |
1 Year: | 34% |
Return on Equity | |
---|---|
10 Years: | 13% |
5 Years: | 14% |
3 Years: | 16% |
Last Year: | 22% |
Balance Sheet
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 |
Reserves | 75 | 85 | 87 | 131 | 177 | 180 | 205 | 217 | 239 | 274 | 306 | 377 | 408 |
38 | 42 | 30 | 20 | 30 | 28 | 0 | 2 | 2 | 6 | 5 | 3 | 4 | |
64 | 66 | 71 | 67 | 71 | 76 | 84 | 95 | 95 | 116 | 106 | 112 | 119 | |
Total Liabilities | 183 | 198 | 193 | 224 | 285 | 290 | 295 | 320 | 341 | 401 | 423 | 498 | 535 |
72 | 67 | 49 | 44 | 87 | 83 | 77 | 91 | 84 | 88 | 80 | 83 | 83 | |
CWIP | 1 | 3 | 5 | 5 | 9 | 5 | 5 | 2 | 1 | 1 | 3 | 7 | 14 |
Investments | 0 | 16 | 16 | 48 | 59 | 68 | 113 | 122 | 138 | 183 | 193 | 273 | 296 |
110 | 111 | 122 | 127 | 130 | 134 | 99 | 106 | 119 | 130 | 148 | 135 | 142 | |
Total Assets | 183 | 198 | 193 | 224 | 285 | 290 | 295 | 320 | 341 | 401 | 423 | 498 | 535 |
Cash Flows
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
20 | 21 | 28 | 68 | 20 | 30 | 32 | 30 | 37 | 40 | 11 | 46 | |
-9 | -24 | -9 | -38 | -36 | -11 | -19 | -20 | -37 | -40 | -5 | -33 | |
-8 | -2 | -18 | -18 | 7 | -5 | -17 | -10 | -2 | -2 | -6 | -8 | |
Net Cash Flow | 3 | -5 | 1 | 12 | -10 | 15 | -4 | 0 | -2 | -1 | -1 | 4 |
Ratios
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 52 | 54 | 47 | 41 | 41 | 35 | 25 | 34 | 29 | 29 | 32 | 30 |
Inventory Days | 165 | 191 | 176 | 187 | 217 | 173 | 151 | 148 | 151 | 124 | 149 | 126 |
Days Payable | 110 | 135 | 103 | 102 | 117 | 127 | 102 | 132 | 104 | 96 | 95 | 98 |
Cash Conversion Cycle | 107 | 111 | 120 | 126 | 141 | 81 | 74 | 50 | 76 | 57 | 87 | 58 |
Working Capital Days | 61 | 57 | 52 | 48 | 61 | 45 | 22 | 18 | -8 | -29 | 19 | -10 |
ROCE % | 14% | 18% | 18% | 17% | 15% | 7% | 18% | 14% | 12% | 17% | 17% | 28% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
15 Nov - Newspaper Publication of Extract of Unaudited Financial Results for the Quarter and Half Year ended September, 2024
-
Announcement under Regulation 30 (LODR)-Meeting Updates
14 Nov - Investment of INR 78.75 Lacs in Sunsure Solarpark.
-
Announcement under Regulation 30 (LODR)-Change in Management
14 Nov - Investment of INR 78.75 Lacs in Sunsure Solarpark.
- Considered, Approved And Taken On Record The Unaudited Financial Result For The Quarter Ended 30Th September, 2024 14 Nov
-
Board Meeting Outcome for Unaudited Financial Results For The Quarter And Half Year Ended 30Th September 2024 And Other Business
14 Nov - Proposed investment of INR 78.75 Lacs in Sunsure Solarpark.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Business Overview:[1]
ADL is a part of the Kolkata-based Kothari Group. It is a prominent drug house, which is in the field of manufacturing Pharmaceutical Formulations, Infusion Solutions, Herbal Dosage Forms, Bulk Drugs, etc. Company is in strategic liaison with academic institutes like the Indian Institute of Chemical Biology (CSIR) & Department of Biotechnology, Calcutta University for outsourcing research.